DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report published on Monday morning. The firm issued a hold rating on the stock.

DBVT has been the topic of several other research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a research note on Tuesday, December 10th. HC Wainwright lifted their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 24th.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $3.18 on Monday. The firm has a market capitalization of $65.41 million, a price-to-earnings ratio of -0.71 and a beta of 0.64. The business has a fifty day moving average price of $3.46 and a 200-day moving average price of $3.98. DBV Technologies has a one year low of $2.20 and a one year high of $10.70.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.